Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 466-473

  Doherty, Annette M ^a  

^a Institut de Recherche Jouveinal   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ANIMAL EXPERIMENT; ARTERITIS; ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG SAFETY; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; RAT; REVIEW; RHEUMATOID ARTHRITIS; VOMITING;

ANIMALIA; EMESIS;

EID: 0033178884     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80068-4     Document Type: Article

References (83)

1. Torphy JT: Phosphodiesterase isoenzymes. Molecular targets for novel antiasthma agents. J Resp Crit Care Med 1998, 157:351-370. This is an excellent review of the phosphodiesterase isozymes covering their molecular biology, mechanistic effects, in vitro and in vivo biology.
2. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB: Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 1998, 246:570-577. This is a recent publication describing the discovery of a new class of cAMP specific isozymes in the PDE family, known as PDE 8.
3. De Brito FB, Souness JE, Warne PJ: Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease. Emerg Drugs 1997, 2:249-268.
4. Swinnen JV, Josef DR, Conti M: Molecular cloning of rat homologues of the drosophila melangaster dunce cAMP phosphodiesterase: Evidence for a family of genes. Proc Natl Acad Sci USA 1989, 86:5325-5329.
5. Colicelli J, Birchmeier C, Michaeli J, O'Neill K, Riggs M, Wigler M: Isolation and characterization of a mammalian gene encoding a high affinity cAMP phosphodiesterase. Proc Natl Acad Sci USA 1989, 86:3599-3603.
6. Jin S-L, Swinnen JV, Conti M: Characterization of the structure of a low Km rolipram sensitive cAMP phosphodiesterase. J Biol Chem 1992, 267:18929-18939.
7. McLaughlin MM, Cieslinski LB, Burman M, Torphy TJ, Livi GP: A low Km rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: Cloning and expression of cDNA, biochemical characterization of recombinant protein and tissue distribution of mRNA. J Biol Chem 1993, 268:6470-6476.
8. Obernolte R, Bhakta S, Alvarez R, Bach C, Zuppan P, MUlkins M, Jarnagin K, Shelton ER: The cDNA of a human lymphocyte cyclic AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene 1993, 129:239-247.
9. Monaco L, Vicini E, Conti M: Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. J Biol Chem 1994, 269:347-357.
10. Baecker PA, Obernolte R, Bach C, Yee C, Shelton ER: Isolation of cDNA encoding a human rolipram sensitive cyclic AMP phosphodiesterase (PDE IVD). Gene 1994, 138:253-256.
11. Owens RJ, Lumb S, Rees-Milton K, Russell A, Baldock D, Lang V, Crabbe T, Ballersteros M, Perry MJ: Molecular cloning and expression of a human phosphodiesterase 4C. Cell Signal 1997, 9:575-585.
12. Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffman R, Wilkinson I, Farrell C, Houslay MD: Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 1997, 328:539-548.
13. Hustun E, Lumb S, Russell A, CAtterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, Houslay MD: Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J 1997, 328:549-558.
14. Chujor CS, Hammerschmid F, Lam C: Cyclic nucleotide phosphodiesterase 4 subtypes are differently expressed by primary keratinocytes and human epidermoid cell lines. J Invest Dermatol 1998, 110:287-291.
15. Ma D, Wu P, Egan RW, Billah MM, Wang P: Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 1999, 55:50-57. This paper covers the activation of one of the subtypes of PDE 4, namely 4B, by LPS indicating its potential role in inflammatory disorders. The paper also describes the inhibition of IL-10 in human monocytes.
16. Iona S, Cuomo M, Bushnik T, Sette C, Hess M, Shelton ER, Conti M: Characterization of the rolipram sensitive, cyclic AMP-specific phosphodiesterases: Identification and differential expression of immunologically distinct forms in the rat brain. Mot Pharmacol 1998, 53:23-32. This study uses monoclonal and polyclonal antibodies to each of the PDE 4 subtypes to characterise their localisation in different regions of the rat brain.
17. Jin SL, Bushnik T, LAn L, Conti M: Subcellular localization of the rolipram sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. J Biol Chem 1998, 273:19672-19678. Data in this paper show that three PDE 4D splicing variants are targeted to discrete subcellular compartments and that hormonal activation causes temporal activation.
18. Jiang X, Paskind M, Weltzien R, Epstein PM: Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 i mitogen-stimulated and leukemic human lymphocytes. Cell Biochem Biophys 1998, 28:135-160.
19. Erdogan S, Houslay M: Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE-3 and inducing PDE4D1 and PDE4D2 splice variants as well as down regulating a novel PDE4A splice variant Biochem J 1997, 321:165-175.
20. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS: Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterases 4A and 4B isoforms. J Neurosci 1999, 19:610-618.
21. Hoffman R, Wilkinson IR, McCallum JF, Engels P, Houslay MD: cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of ser-54: Generation of a molecular model. Biochem J 1998, 333:139-149.
22. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH et al.: Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 1997, 36:14250-14261.
23. Mackenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RG, Houslay MD: Stimulation of p70S6 kinase via a growth hormone controlled phosphatidylinositol 3-kinase pathway leads to the activation of PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc Natl Acad Sci USA 1998, 95:3549-3554. The involvement of PDE4A5 in cellular differentiation stimulated by growth hormone is described in this paper.
24. Seybold J, Newton R, Wright L, Finney PA, Suttorp N, Barnes PJ, Adcock IM, Giembycz MA: Induction of phosphodiesterase 3B, 4A4, 4D1, 4D2, and 4D3 in jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonist. Potential role in beta2-adrenoreceptor desensitization. J Biol Chem 1998, 273:20575-20588.
25. Banner KH, Page CP: Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Allerg Int 1996, 45:125-132.
26. Weston MC, Anderson N, Peachell PT: Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol 1997, 121:287-295.
27. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang S-K: Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997, 282:505-512.
28. Essayan DM, Huang S-K, Kagey-Sobotka A, Lichtenstein MD: Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997, 99:28-37.
29. Kaminuma O, Mori A, Wada K, Kikkawa H, IKezama K, Okudaira H: A selective type 4 phosphodiesterase inhibitor, T-440, modulates intracellular cyclic AMP level and interleukin-2 production of Jurkat cells. Immunopharmacology 1998, 38:247-252.
30. Essayan DM, Kagey-Sobotka A, Lichenstein LM, Huang S-K: Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergan-specific human T lymphocyte clones. Biochem Pharmacol 1997, 53:1055-1060.
31. Gantner F, Gotz C, Gekeler V, SChudt C, Wendel A, Hatzelmann A: Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 1998, 123:1031-1038.
32. Crocker IC, Ohia SE, Charch MK, Towley RG: Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol 1998, 102:797-804.
33. Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A: Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals; a comparative study. J Allergy Clin Immunol 1997, 100:527-535.
34. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson J-A: Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a low affinity phosphodiesterase 4 conformer. Br J Pharmacol 1996, 118:649-658.
35. Bigler A, Sigmund B, Emmerich U, Baumann KH, Hartmann G, Endres S: Anti-inflammatory activities of cAMP-elevating agents: Enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998, 63:101-107.
36. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A: In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumor necrosis factor-α release by PDE inhibitors. Br J Pharmacol 1997, 121:221-231.
37. Brideau C, Van Standen C, Styler A, Rodger IW, Chan CC: The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-a and leukotriene B4 in novel human whole blood assay. Br J Pharmacol 1999, 126:979-988.
38. Rose RJ, Lui H, Palmer D, Maurice DH: Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 1997, 122:233-240.
39. Santamaria L, Palacios JM, Beleta J: Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. Br J Pharmacol 1997, 121:1150-1154.
40. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK: Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996, 118:1727-1735.
41. Blease K, Burke-Gaffney A, Hellewell PG: Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterase 3 and 4. Br J Pharmacol 1998, 124:229-237. This study shows that combined inhibition of PDE-3 and 4 is necessary to inhibit eosinophil adhesion to activated human lung microvascular endothelial cells.
42. Takei K, Tokuyama K, Kato M, Morikawa A: Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages. Pharmacology 1998, 57:1-7.
43. Robichaud A, Tattersall FD, Choudhury I, Rodger IW: Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 1999, 38:289-297.
44. Ukita T, Sugahara M, Terakawa Y, Kurida T, Wada K, Nakata A, Ohmachi Y, Kikkawa H, Ikezawa K, Naito K: Novel potent and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: Synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives. J Med Chem 1999, 42:1088-1099.
45. Souness JE, Rao S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997,9:227-236.
46. Larson JL, Pino MV, Geiger LE, Simeone CR: The toxicity of repeated exposure of rolipram, a type IV phosphodiesterase inhibitor in rats. Pharmacol Toxicol 1996, 78:7844-7849.
47. Nyska A, Herbert RA, Chan PC: Theophylline-induced mesenteric periarteritis in F344/N rats. Arch Toxicol 1998, 72:731-737.
48. Kumari M, Cover PC, Poyser RH, Buckingham JC: Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type 4 phosphodiesterase inhibitors: In vitro and in vivo studies. Br J Pharmacol 1997, 121:459-468.
49. Fisch JD, Sehr B, Conti M: Enhancement of motility and acrosome reaction in human spermatozoa: Differential activation by type-specific phosphodiesterase inhibitors. Hum Reprod 1998, 13:1248-1254.
50. Leroy MJ, Mehats C, Duc-Goiran P, Tanguy G, Robert B, Dallot E, Mignot TM, Grange G, Ferre F: Effect of pregnancy on PDE-4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium. Cell Signal 1999, 11:31-37.
51. TsAfriri A, Chun SY, Zhang R, Hsueh AJ, Conti M: Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: Studies using selective phosphodiesterase inhibitors. Devel Biology 1996, 178:393-402.
52. Tavakkoli A, Rees PJ: Drug treatment of asthma in the 1990s. Drugs 1999, 57:1-8.
53. Turner CR, Cohan VL, Cheng JB, Showell HJ, Pazoles CJ, Watson JW: The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J Pharmacol Exp Ther 1996, 278:1349-1355.
54. Dent G, Poppe H, Egerland J, Marx D, Szelenyi I, BranscheiD D, Magnussen H, Rabe KF: Effects of a selective PDE-4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther 1998, 11:13-21.
55. Hughes B, Howat D, Lisle H, Holbrook M, James T, Gozzard N, Blease K, Hughes P, Kingaby R, Warrellow G et al.: The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br J Pharmacol 1996, 118:1183-1191.
56. Kaminuma O, Kikkawa H, Matsubara S, Ikezawa K: Effect of T-440, a novel type IV phosphodiesterase inhibitor on allergen induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs. Int Arch Allergy Immunol 1997, 112:406-411.
57. Manabe H, Akuta K, Sejimo H, Kawasaki H, Nukui E, Ichikura M, Kase H, Kawakita T, Suzuki F, Kitamura S et al: Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor, Eur J Pharmacol 1997, 332:97-107.
58. Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttman MA, Hay DWP, Gorycki PD, Christensen SB, Torphy TJ: Antiasthmatic activity of the second generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (ariflo) in the guinea pig. J Pharmacol Exp Ther 1998, 287:988-995. This paper describes the pharmacological activity of the important PDE 4 inhibitor Ariflo (SB 207499) which is currently in clinical development for asthma, COPD and atopic dermatitis.
59. Matsubara S, Fushimi K, Kaminuma O, Kikkawa H, Ikezawa K, Naito K: Prevention of ozone-induced airway hyperresponsiveness and epithelial injury by phosphodiesterase inhibitors in guinea pigs. Environ Toxicol Pharmacol 1997, 3:201-209.
60. Fujii K, Kohrogi H, Iwagoe H, Hamamoto J, Hirata N, Goto E, Kawano O, Wada K, Yamagata S, Ando M: Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen. J Pharmacol Exp Ther 1998 284:162-169.
61. Silvestri J, Graul A, Castaner J: SB-207499 (Ariflo TM). Drugs Future 1998, 23:607-615. This is a review covering the chemistry and biology of ArifloTM
62. Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH: The effect of a novel orally active selective PDE-4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997 10:1008-1014.
63. Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, Dewolf WE, Barbette MS, Underwood DC, Griswold DE et al.: 1,4-cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 1998, 41:821-835.
64. Burnouf C, Pruniaux M-P, Szilagyi C: Phosphodiesterase inhibitors. Annu Rep Med Chem 1998, 33:91-109. This is a comprehensive review of all the recent PDE 4 inhibitors discovered. It covers the structures of a range of interesting compounds and the most important pharmacology of each agent or class of structures. The review also discusses therapeutic indications for PDE 4 inhibitors.
65. Barnes PJ: Chronic obstructive pulmonary disease: New opportunities for drug development. Trends Pharmacol Sci 1998, 19:415-423. This is an excellent review which covers the biology of the disease COPD and also discusses promising potential mechanistic directions to treat this disease.
66. Compton CH, Gubb J, Cedar E, Bakst A, Nieman RB, Amit O, Ayres J, Brambilla A: The efficacy of ariflo (SB207499), a second generation, oral PDE4 inhibitor in patients with COPD. Am J Respir Crit Care Med 1999, 159:A522.
67. Wagner RS, Smith CJ, Taylor AM, Rhoades RA: Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 1997, 282:1 650-1657.
68. Miotla JM, Teixeira MM, Hellewell PG: Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am J Respir Cell Mol Biol 1998, 18:411-420.
69. Gonccalves de Moraes VL, Singer M, Vargaftig BB, Chignard M: Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br J Pharmacol 1998, 123:631-636. In this study the target cell for LPS induced TNF production and neutrophil infiltration is investigated. Alveolar macrophages are implicated in the responses to LPS.
70. Nymaan U, Mussener A, Larsson E, Lorentzen J, Klareskog L: Amelioration of collagen ll-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram. Clin Exp Immunol 1997, 108:415-419.
71. Navikas V, Matusevicius D, Soderstrom M, PiRskanen R, FredrikSon S, Link H: The phosphodiesterase i.v. Inhibitor rolipram in vitro reduces the numbers of MBP-reactive INFγ and TNFα mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Clin Neuropharmacol 1998, 21:236-244.
72. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barbette MA, Grous M, Christensen S, Torphy TJ: SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998, 287:705-711. This paper describes the effects of ArifloTM on cytokine and interleukin production in vivo.
73. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E: Rolipram, a type iv-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting potentiation and improves memory. Proc Natl Acad Sci USA 1998, 95:15020-15025. This is the first demonstration that a PDE-4 inhibitor can improve cognition and points the direction to this neurological disorder as a potential therapeutic direction for PDE4 inhibitors
74. Block F, Tondar A, Schmidt W, Schwartz M: Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats. Neuroreport 1997, 8:3829-3832.
75. Belayev L, Busto R, Ikeda M, Rubin LL, Kajiwara A, Margan L, Ginsberg MD: Protection against blood brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: A quantitative study. Brain Res 1998, 787:277-285.
76. Knapp CM, Foye MM, Ciraulo DA, Kornetsky C: The type IV phosphodiesterase inhibitors, ro 20-1724 and rolipram, block the initiation of cocaine self-administration. Pharmacol Biochem Behav 1999, 62:151-158.
77. Lelkes Z, Alfoldi P, Erdos A, Benedek G: Rolipram, an antidepressant that increases the availability of cAMP transiently enhances wakefulness in rats. Pharmacol Biochem Behav 1998, 60:835-839.
78. Rogers A, Hurwitz L: Crohn's disease. Clin Persp Gastroenterol 1998,47-59. An excellent review on the epidemiology, pathogenesis, diagnosis and management of Crohn's disease.
79. Shafer SH, Phelps SH, Williams CL: Reduced DNA synthesis and cell viability in small lung call carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 1998, 56:1229-1236.
80. Kil DH, Lerner A: Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 1998, 92:2484-2494.
81. Liang L, Beshay E, Prud-Homme GJ: The phosphodiesterase inhibitors pentoxifylline, and rolipram prevent diabetes in NOD mice. Diabetes 1998, 47:570-575.
82. Miyamoto K, Waki Y, Horita T, Kasugai S, Ohya K: Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 1997, 54:613-617.
83. Becker AJ, Steif CG, Meyer M, Truss MC, Forssman WG, Jonas U: The effect of the specific phosphodiesterase IV inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo. J Urology 1998, 160:920-925.